Holding(s) in Company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: 

Allergy Therapeutics plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: 

Azure Ventures Limited

4. Full name of shareholder(s)  (if different from 3.):

N/A

5. Date of the transaction and date on which the threshold is crossed or reached: 

10 July 2009

6. Date on which issuer notified:

10 July 2009

7. Threshold(s) that is/are crossed or reached: 

40%, 41%, 42%

8. Notified details:

A: Voting rights attached to shares 

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights 

Direct

Direct 

Indirect

Direct

Indirect

GB00B02LCQ05

104,166,666

104,166,666

116,666,666

116,666,666

N/A

42.19%

N/A

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date 

Exercise/  Conversion Period 

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments 

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date 

Exercise/ Conversion period 

Number of voting rights instrument refers to

% of voting rights 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

116,666,666

42.19%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

One of the ultimate beneficial owners of Azure Ventures Limited is Alejandro Weinstein who is a director of Allergy Therapeutics plc. 

14. Contact name:

Sarah Hooker - Reed Smith LLP

15. Contact telephone number:

020 3116 2987